MAPC Therapeutics Without Immunosuppression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for hypoxic-ischemic brain injury and other brain-related conditions are limited, with a need for more effective therapies that do not require adjunctive immunosuppressive treatment, as existing stem cell therapies are either immunogenic, have limited differentiation potential, or pose ethical concerns.

Innovation Solution

The use of multipotent adult progenitor cells (MAPCs) that can differentiate into multiple cell types without being immunogenic, allowing for effective treatment of injuries and diseases without the need for immunosuppressive measures, and can be administered alone or with other therapeutic agents.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If stem cell therapies are used to treat hypoxic-ischemic brain injury, then therapeutic benefits are improved, but immunogenicity requires adjunctive immunosuppressive treatment

Engineering Contradiction:

Improvetherapeutic benefitsVSAvoidimmunogenicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent segments the stem cell population into specific subsets with defined immunogenic characteristics. By isolating and using only those stem cell populations that exhibit low immunogenicity, the therapy achieves therapeutic benefits while avoiding the harmful immunogenic response that would require suppressive treatment.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent applies local quality by treating different stem cell populations differently based on their immunogenic properties. Specifically, certain stem cell subsets are selected and prepared to have reduced immunogenicity, allowing them to be administered without adjunctive immunosuppression while still providing therapeutic benefits.

Inventive Principle:

Principle #3Local quality

2Adaptability or versatility

If embryonic stem cells are used for treatment, then differentiation potential is improved, but ethical concerns and immunogenicity worsen

Engineering Contradiction:

Improvedifferentiation potentialVSAvoidethical concerns and immunogenicity

Core Design Contradiction:

Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

Instead of using embryonic stem cells and attempting to reduce their immunogenicity, the patent inverts the approach by using adult stem cells that naturally exhibit low immunogenicity. This inversion allows the therapy to avoid both ethical concerns and immunogenicity issues while maintaining therapeutic effectiveness through the selection of appropriate adult stem cell populations.

Inventive Principle:

Principle #13The other way round (Inversion)

Data Source

PatentUS11992507B2MAPC therapeutics without adjunctive immunosuppressive treatment

Publication Date: 2024.05.28 HEALIOS KK

AI summary

The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like with MAPCs, without the need for adjunctive immunosuppressive treatment.